Dan, I would love to, but I don't know how (to do such searches..and properly
to get the best collection of articles and most recent) and/or the
alt.support.cancer newsgroup takes up most of my time.

http://www.rxlist.com/cgi/generic3/striant_wcp.htm
Geriatric patients and other patients with clinical or demographic
characteristics that are recognized to be associated with an increased risk of
prostate cancer should be evaluated for the presence of prostate cancer prior
to initiation of testosterone replacement therapy. In men receiving
testosterone replacement therapy, surveillance for prostate cancer should be
consistent with current practices for eugonadal men

2. Liver function, prostatic specific antigen, cholesterol, and high-density
lipoprotein should be checked periodically.

Carcinogenesis, mutagenesis, impairment of fertility

Animal data: Testosterone has been tested by subcutaneous injection and
implantation in mice and rats. In mice, the implant induced cervical-uterine
tumors, which metastasized in some cases. There is suggestive evidence that
injection of testosterone into some strains of female mice increases their
susceptibility to hepatoma. Testosterone is also known to increase the number
of tumors and decrease the degree of differentiation of chemically induced
carcinomas of the liver in rats.

Human data: There were rare reports of hepatocellular carcinoma in patients
receiving long-term therapy with androgens in high doses. Withdrawal of the
drugs did not lead to regression of the tumors in all cases.

Striant™ has been evaluated in patients for 1 year without reports of cancer
related to the product. However, safety in patients beyond 1 year has not been
established.

Geriatric patients treated with androgens may be at an increased risk for the
development of prostatic hyperplasia and prostatic carcinoma.

Geriatric patients and other patients with clinical or demographic
characteristics that are recognized to be associated with an increased risk of
prostate cancer should be evaluated for the presence of prostate cancer prior
to initiation of testosterone replacement therapy.

In men receiving testosterone replacement therapy, surveillance for prostate
cancer should be consistent with current practices for eugondal men.

<then we have to get into defining what they mean by geriatric or demographic
characteristics>

It would also be interesting (to me) to have a study of men who usually run
(high)er on testosterone levels and see which, over a longer period, do or
don't develop prostate cancer.  Because perhaps that's a preventative method,
to monitor and balance the hormone/testosterone levels much earlier in life?

This web page is usually a solid source
http://www.cancerhelp.org.uk/help/default.asp?page=2718 and
"Prostate cancer cells need testosterone to grow. "  They do research and
there is a UK phone number there.
Do you suppose someone on this newsgroup from UK could call them and ask them
for references/sources of that statement?

Or ditto for this one?http://www.cancerbacup.org.uk/QAs/934
Most prostate cancers need the male hormone testosterone on order to grow.
(their typo, not mine)
They have an "order publications" there too.

Here is my concern for butting in.
It's pretty well known, especially as we age, that we have cancer cells
floating around our bodies. If there's a risk of causing the cancer cells to
either start growing faster or spread faster, don't males have the right to
know that information before deciding on whether they want to take extra
testosterone (or not)?

then especially in someone who has already been diagnosed and treated with
PCA, seems dangerous to me, for someone to consider supplementing their
testosterone after treatment?? (I think I saw a poster say that was his
intent)..hence why I started this thread).

So if you can find someone, instead of me, I'd watch for updates with
interest.
J